

Applicant: Townsend et al.  
USSN 09/877,987  
Filed: June 8, 2001  
Dkt: D009NP;30436.53USU1  
Page: 2

Please amend the subject application as follows.

**In the Claims**

Please amend the following claims

C1  
16. (amended) The method of claim 5, wherein the soluble CTLA4 molecule is CTLA4Ig (ATCC 68629) or L104EA29YIg (ATCC PTA-2104); wherein the soluble CD28 molecule is CD28Ig (ATCC 68628); wherein the soluble B7 molecule is B7Ig (ATCC 68627); wherein the anti-B7 monoclonal antibody is ATCC HB-253, ATCC CRL-2223, ATCC CRL-2226, ATCC HB-301 or ATCC HB-11341; wherein the anti-CTLA4 monoclonal antibody is ATCC HB-304; and wherein the anti-CD28 monoclonal antibody is mAb 9.3.4

C2  
23. (amended) The pharmaceutical composition of claim 22, wherein the soluble CTLA4 molecule is CTLA4Ig (ATCC 68629) or L104EA29YIg (ATCC PTA-2104); wherein the soluble CD28 molecule is CD28Ig (ATCC 68628); wherein the soluble B7 molecule is B7Ig (ATCC 68627); wherein the anti-B7 monoclonal antibody is ATCC HB-253, ATCC CRL-2223, ATCC CRL-2226, ATCC HB-301 or ATCC HB-11341; wherein the anti-CTLA4 monoclonal antibody is ATCC HB-304; and wherein the anti-CD28 monoclonal antibody is mAb 9.3.4

C3  
31. (amended) The kit of claim 30, wherein the soluble CTLA4 molecule is CTLA4Ig (ATCC 68629) or L104EA29YIg (ATCC PTA-2104); wherein the soluble CD28 molecule is CD28Ig (ATCC 68628); wherein the soluble B7 molecule is B7Ig (ATCC 68627); wherein the anti-B7 monoclonal antibody is ATCC HB-253, ATCC CRL-2223, ATCC CRL-2226, ATCC HB-301 or ATCC HB-11341; wherein the anti-CTLA4 monoclonal antibody is ATCC HB-304; and wherein the anti-CD28 monoclonal antibody is mAb 9.3.4